FDA Brief

Warning letters Drugs

FDA warning letter to

ImmunityBio, Inc.

High riskIssued Mar 13Posted Mar 24The Office of Prescription Drug Promotion (OPDP)

FDA says ImmunityBio's Anktiva TV ad and podcast falsely claim it can cure or prevent all cancers.

What happened

FDA's Office of Prescription Drug Promotion reviewed a direct-to-consumer TV ad submitted under Form FDA 2253 and a podcast titled "Is the FDA BLOCKING Life Saving Cancer Treatments?" that was also available on ImmunityBio's website; the FDA Bad Ad Program also received complaints. FDA found the TV ad and podcast false or misleading because they suggested Anktiva can cure or prevent all cancers, treat all cancers or lung cancer after checkpoint inhibitor failure, work as a single agent or subcutaneous injection, and because they omitted risk information and the full approved indication. FDA also said the podcast was not submitted at the time of initial publication as required.

What FDA found

  1. The TV ad and podcast made unsupported efficacy claims that Anktiva can keep cancer from coming back or cure cancer.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5), (e)(7)(viii)
  2. The podcast suggested Anktiva can treat all cancers, lung cancer after checkpoint inhibitor failure, and prevent cancer after radiation exposure, which are unapproved uses with no adequate directions in the labeling.

    21 U.S.C. 352(f)(1); 331(a); 21 CFR 201.5; 201.100; 201.115; 201.128
  3. The podcast and TV ad suggested Anktiva is given as a single jab or subcutaneous injection, but the drug is approved for intravesical use only and must not be given subcutaneously, intravenously, or intramuscularly.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5), (e)(7)(viii)
  4. The podcast included no risk information, and the TV ad put risk information after the screen faded to black, so risks were not presented with prominence comparable to benefits.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5), (e)(7)(viii)
  5. The promotions omitted the full approved indication, including that Anktiva is for use in combination with BCG in adults with BCG-unresponsive NMIBC with CIS with or without papillary tumors.

    21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(5), (e)(7)(viii)
  6. The podcast was not submitted to FDA under Form FDA 2253 at the time of initial publication or dissemination.

    21 CFR 314.81(b)(3)(i)

What FDA wants

FDA tells ImmunityBio to take immediate action, including ceasing the misleading promotions. Within 15 working days, the company must respond, list other similar Anktiva communications with their Form FDA 2253 dates, explain its discontinuation plan or plan to stop distributing Anktiva, and provide a corrective communications plan.

Who should pay attention

  • oncology drugmakers and their promotional review teams
  • companies that advertise prescription drugs directly to consumers
  • drugmakers using podcasts or company websites to promote products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Amgen Inc.

    FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.

    Medium